Molecular Cancer
Q1 Journal
Open Access
Journal
Country
United Kingdom
Western Europe
Subject Area and Category
Biochemistry, Genetics and Molecular Biology
└
Cancer Research
Q1
└
Molecular Medicine
Q1
└
Oncology
Q1
Publisher
SJR 2025
9.908
Q1
SJR Score
H-Index
242
Citations / Doc (2yr)
32.77
Total Docs. (latest)
300
Total Citations (3yr)
22,706
Publication type
Journals
ISSN
14764598
Coverage
2002-2026
Journal Rank
#89
Subject Categories
Cancer Research
Q1
Molecular Medicine
Q1
Oncology
Q1
Subject Areas
Aims & Scope
Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view.
Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer.
Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.
Abstracting & Indexing
Scopus
Google Scholar
Directory of Open Access Journals (DOAJ)
Web of Science
Medline
PubMed
Embase
Detailed Metrics
| Total Docs. (latest) | 300 |
| Total Docs. (3 years) | 666 |
| Total Refs. | 47,076 |
| Total Citations (3 years) | 22,706 |
| Citable Docs. (3 years) | 558 |
| Citations / Doc. (2 years) | 32.77 |
| Ref. / Doc. | 156.92 |
| % Female | 42.4% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.